EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1137-1145 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1137 - 1145
Section Les anticorps biosimilaires
DOI https://doi.org/10.1051/medsci/2019214
Publié en ligne 6 janvier 2020
  1. Guidelines on evaluation of similar biotherapeutic products 5SBPs, 2010; p. 1–34. [Google Scholar]
  2. European Medecines Agency cfMpfHU. Guideline on similar biological medecinal products containing monoclonal antibodies - non clinical and clinical issues. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientif_guideline/2012/06/WC500128686pdf. 2012. [Google Scholar]
  3. Agency EM. Guideline on similar biological products containing biotechnology-derived proteins as active sustance: non-clinical and clinical issues. http://wwwemaeuropaeu/docs/en_GB/document_library/Scientif_guideline/2015/01/WC500180219pdf. 2015. [Google Scholar]
  4. Agencies UEM. Scientific considerations in demonstrating biosimilarity to a reference product, Guidance for Industry. http://wwwfdagov/downloads/drugs/guidanceComplianceRegulatoryInformation/Guidances/UCM291128pdf. 2015. [Google Scholar]
  5. Vezér B, Buzás Z, Sebeszta M, Zrubka Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin 2016 ; 32: 829–834. [CrossRef] [PubMed] [Google Scholar]
  6. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originatoir infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab [NOR-SWITCH]: a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017 ; 389: 2304–2316. [CrossRef] [PubMed] [Google Scholar]
  7. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017 ; 76: 1426–1431. [CrossRef] [PubMed] [Google Scholar]
  8. Agence Nationale de sécurité du médicament et des produits de santé. État des lieux sur les médicaments biosimilaires. Paris: Ansm, 2016: 1–28. [Google Scholar]
  9. ANSM. Analyse des ventes de médicaments en France en 2013; 2014; p. 1–36 [http://www.ansm.sante.fr/content/download/64305/824219/version/2/file/ANSM.Analyse-Ventes-Medicaments.2013.pdf]. [Google Scholar]
  10. Ghersinick-09072. In: Dépenses de médicaments de l’année 2014 et du premier semestre 2015. Paris: Caisse nationale d’assurance maladie, 2015: 1–24. [Google Scholar]
  11. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017 ; 76: 355–363. [CrossRef] [PubMed] [Google Scholar]
  12. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017 ; 76: 346–354. [CrossRef] [PubMed] [Google Scholar]
  13. Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris. France. Semin Arthritis Rheum 2018 ; 47: 741–748. [CrossRef] [Google Scholar]
  14. Scherlinger M, Germain V, Labadie C, et al. FHU ACRONIM. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine 2018 ; 85: 561–567. [CrossRef] [PubMed] [Google Scholar]
  15. Arrêté du 3 août 2018 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville. Journal Officiel 17 août 2018. [Google Scholar]
  16. Arrêté du 12 février 2019 relatif à l’expérimentation pour l’incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville. Journal Officiel 15 février 2019. [Google Scholar]
  17. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005 ; 353: 1734–1736. [Google Scholar]
  18. Pivot X, Aulagner G, Blay JY, et al. Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations. Anticancer Drugs 2015 ; 26: 1009–1016. [CrossRef] [PubMed] [Google Scholar]
  19. Hurst S, Ryan AM, Ng CK, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®). BioDrugs 2014 ; 28: 451–459. [CrossRef] [PubMed] [Google Scholar]
  20. Pivot X, Curtit E, Lee YJ, et al. A Randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects. Clin Ther 2016; 38: 1665–73e3. [CrossRef] [PubMed] [Google Scholar]
  21. Pivot X, Deslypere JP, Park LS, Kim MJ, Lee W, Lee J. A randomized phase I study comparing the pharmacokinetics of HD201, a trastuzumab biosimilar, with European Union-sourced herceptin. Clin Ther 2018 ; 40: 396–405 e4. [Google Scholar]
  22. Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol 2018 ; 81: 505–514. [CrossRef] [PubMed] [Google Scholar]
  23. Hanes V, Chow V, Zhang N, Markus R. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol 2017 ; 79: 881–888. [CrossRef] [PubMed] [Google Scholar]
  24. Morita J, Tanaka M, Nomoto M, et al. Pharmacokinetic bioequivalence, safety, and immunogenicity of DMB-3111, a trastuzumab biosimilar, and trastuzumab in healthy Japanese adult males: results of a randomized trial. BioDrugs 2016 ; 30: 17–25. [CrossRef] [PubMed] [Google Scholar]
  25. Zhou X, Yu J, Wang W, et al. A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients. Springerplus. 2015 ; 4: 803. [CrossRef] [PubMed] [Google Scholar]
  26. Yin D, Barker KB, Li R, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327–01). Br J Clin Pharmacol 2014 ; 78: 1281–1290. [CrossRef] [PubMed] [Google Scholar]
  27. Wisman LA, De Cock EP, Reijers JA, et al. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Clin Drug Investig 2014 ; 34: 887–894. [Google Scholar]
  28. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005 ; 56: 361–369. [CrossRef] [PubMed] [Google Scholar]
  29. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003 ; 21: 3965–3971. [CrossRef] [PubMed] [Google Scholar]
  30. von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 2018 ; 19: 987–998. [CrossRef] [PubMed] [Google Scholar]
  31. Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017 ; 18: 917–928. [CrossRef] [PubMed] [Google Scholar]
  32. Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and Immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol 2018 ; 36: 968–974. [CrossRef] [PubMed] [Google Scholar]
  33. Lammer P, Dank M, Masetti R, et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breaast cancer. Br J Cancer 2018 ; 119: 266–273. [CrossRef] [PubMed] [Google Scholar]
  34. Pivot X, Thierry-Vuillemin A, Villanueva C, Bazan F. Response rates: a valuable signal of promising activity?. Cancer J 2009 ; 15: 361–365. [CrossRef] [PubMed] [Google Scholar]
  35. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 ; 384: 164–172. [CrossRef] [PubMed] [Google Scholar]
  36. Pivot X, Cox DG. A new era for treatment development in HER2-positive breast cancer. Lancet Oncol 2018 ; 19: 160–162. [CrossRef] [PubMed] [Google Scholar]
  37. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA 2017 ; 317: 37–47. [CrossRef] [PubMed] [Google Scholar]
  38. Pegram M, Tan-Chui E, Freyman A, et al. A randomized, double blind study of PF-05280014 (a potential trastuuzmab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast canecr. European Society forMedical Oncology (ESMO). 2017. [Google Scholar]
  39. Pivot X, Bondarenko I, Nowecki Z, et al. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results. Eur J Cancer 2018 ; 93: 19–27. [CrossRef] [PubMed] [Google Scholar]
  40. Kim S, Song J, Park S, et al. Drifts in ADCC-related quality attributes of Herceptin(R): Impact on development of a trastuzumab biosimilar. MAbs 2017 ; 9: 704–714. [CrossRef] [PubMed] [Google Scholar]
  41. Pivot X, Petit T. Can we establish a hierarchy among trastuzumab biosimilar candidates?. Br J Cancer 2018 ; 119: 263–265. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.